Medical School
MD, Shiraz University, Iran
Residency
Hospital of University of Pennsylvania (HUP)
Fellowship
Hospital of University of Pennsylvania (HUP)
Doctoral
PhD, University of Pennsylvania
Abdolmohamad Rostami, MD, PhD
Chairman, Department of Neurology
Nicholas J. Maiale Distinguished Professor in Neurology
Director, Neuroimmunology Laboratory
Contact Information
901 Walnut Street
Suite 400
Philadelphia, PA 19107
215-955-8100
215-955-1390 fax
Chairman, Department of Neurology
Nicholas J. Maiale Distinguished Professor in Neurology
Director, Neuroimmunology Laboratory
Education
Publications
- IL-7Rα on CD4+ T cells is required for their survival and the pathogenesis of experimental autoimmune encephalomyelitis
- IL-37 suppresses CNS autoimmunity by increasing the frequency of Treg cells and reducing CD4 + T cell-derived IL-10 production
- Most recent advances and applications of extracellular vesicles in tackling neurological challenges
- Mouse monocytes express CD127 by immune cells, not LPS
- Retraction Notice to: Neurotrophin 3 Transduction Augments Remyelinating and Immunomodulatory Capacity of Neural Stem Cells (Molecular Therapy (2014) 22(2) (440–450), (S1525001616311650), (10.1038/mt.2013.241))
Board Certification
American Board of Psychiatry and Neurology
Research & Clinical Interests
Multiple Sclerosis is an autoimmune disease of the central nervous system that affects over 400,000 Americans and over two million worldwide. My research focuses on the pathogenesis of multiple sclerosis using the animal model of this disease, experimental autoimmune encephalomyelitis (EAE). At the present, we are focusing on three main areas:
- The role of IL-12/IL-17/IL-23 axis in the pathogenesis of EAE and multiple sclerosis.
Specifically, studies will examine IL-12/IL-17/IL-23 produced by antigen presenting cells (APC) from the periphery (macrophages and dendritic cells) and from the central nervous system (CNS) microglia in EAE. In addition to a better understanding of the pathogenesis of inflammatory demyelination, the information derived from this study will be helpful if these cytokines are to be considered as targets for therapy in MS. - The effect of the Bowman-Birk protease inhibitor on the course of EAE.
This study has the potential to provide a novel, safe, and effective therapy for multiple sclerosis. - Mechanisms of intravenous tolerance in EAE.
This study will elucidate the mechanisms by which intravenous myelin antigens induce tolerance and suppress clinical disease in EAE. This study will provide a novel method for analyzing the migration and functional status of infiltrating cells in the CNS, in particular, and in target organs of other autoimmune diseases. It has the potential as a possible therapy for autoimmune diseases.